Epidemiology of bone metastases

Ryan, Casey; Stoltzfus, Kelsey C.; Horn, Samantha R.; Chen, Hanbo; Louie, Alexander V.; Lehrer, Eric J.; Trifiletti, Daniel M.; Fox, Edward J.; Abraham, John A.; Zaorsky, Nicholas G.

doi:10.1016/j.bone.2020.115783

Cited by 74 publications

(42 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, immunofluorescent staining revealed that CD3+CD25+FOXP3+ Treg cells were colocalized together with RANKL+ cells in CRC tissue. A similar phenomenon was observed in breast cancer metastasis suggesting that CD4+CD25+FOXP3+ Treg cells are the major source of RANKL-promoting [139][140][141]. The percentage of patients is presented as a heatmap with the color intensity corresponding to higher percentage of cases.…”

Section: Rankl Links Periodontal Disease and Cancersupporting

confidence: 55%

See 1 more Smart Citation

Molecular Mechanisms Leading from Periodontal Disease to Cancer

Sobocki

Basset

Bruhn-Olszewska

et al. 2022

IJMS

View full text Add to dashboard Cite

Periodontitis is prevalent in half of the adult population and raises critical health concerns as it has been recently associated with an increased risk of cancer. While information about the topic remains somewhat scarce, a deeper understanding of the underlying mechanistic pathways promoting neoplasia in periodontitis patients is of fundamental importance. This manuscript presents the literature as well as a panel of tables and figures on the molecular mechanisms of Porphyromonas gingivalis and Fusobacterium nucleatum, two main oral pathogens in periodontitis pathology, involved in instigating tumorigenesis. We also present evidence for potential links between the RANKL–RANK signaling axis as well as circulating cytokines/leukocytes and carcinogenesis. Due to the nonconclusive data associating periodontitis and cancer reported in the case and cohort studies, we examine clinical trials relevant to the topic and summarize their outcome.

show abstract

Section: Rankl Links Periodontal Disease and Cancersupporting

confidence: 55%

“…Therefore, RANKL signaling could provide a molecular link between periodontal disease and the prevalence of cancer or cancer metastasis. [139][140][141]. The percentage of patients is presented as a heatmap with the color intensity corresponding to higher percentage of cases.…”

Section: Rankl Links Periodontal Disease and Cancermentioning

confidence: 99%

Molecular Mechanisms Leading from Periodontal Disease to Cancer

Sobocki

Basset

Bruhn-Olszewska

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Death certification is reasonably valid in most countries considered, though variable across some of them. Still, it is possible that a small part of deaths was certified as bone or liver cancer; in case of metastatic disease to bone or liver, however we only considered the primary cancer site [47,48].…”

Section: Discussionmentioning

confidence: 99%

Mortality Trends from Urologic Cancers in Europe over the Period 1980–2017 and a Projection to 2025

Bertuccio

Santucci

Carioli

et al. 2021

European Urology Oncology

View full text Add to dashboard Cite

Background: Patterns and trends in urologic cancer mortality still show geographical differences across Europe. Objective: To monitor mortality trends from urologic cancers, including prostate, testis, bladder, and kidney cancers, in Europe. Design, setting, and participants: We carried out a time-trend analysis for 36 European countries using the official World Health Organization database. Outcome measurements and statistical analysis: We extracted the number of deaths and population data over the 1980-2017 period, and calculated age-standardised (world population) mortality rates for each cancer considered, sex, country, and the European Union (EU) as a whole, at all ages; at ages 35-64 yr for prostate, bladder, and kidney cancers; and at ages 20-44 yr for testicular cancer. For selected major countries, we carried out a joinpoint regression analysis to identify significant changes in trends. We also predicted the number of deaths and rates for 2025, using a logarithmic Poisson count data joinpoint regression model. Results and limitations: Prostate cancer mortality in the EU decreased over recent years, reaching a rate of 10.3/100 000 in 2015 and a projected rate of 8.9/100 000 in 2025. Less favourable trends were observed in eastern Europe, though starting from relatively low rates. Testicular cancer mortality declined over time in most countries, however levelling off in northern and western countries, after reaching very low rates. EU testicular cancer mortality rate in 2015 was 0.3/100 000 at all ages and 0.6/100 000 at ages 20-44 yr. Bladder cancer mortality trends were less favourable in central and eastern countries compared to northern and western ones. The EU rates in 2015 were 5.1/100 000 men and 1.1/100 000 women. Kidney cancer mortality showed less favourable trends, with a slight increase in men and stable rates in women over the past decade in the EU. Conclusions: Mortality from prostate, testis, and bladder cancers, but not from kidney cancer, declined in most European countries, with less favourable trends in most eastern countries.

show abstract

“…Based on data from a Danish cohort study, Svensson and colleagues reported that in the period from 1994 to 2012 the 5-year survival rate after diagnosis of bone metastasis was only 1% for lung cancer, 3% for colon cancer, 5% for kidney and melanoma, 6% for prostate cancer, and 13% for breast cancer [7]. These numbers are supported by other reports covering the same period for Danish and international cohorts [8][9][10][11][12][13]. Survival rates are likely to have improved since then [14][15][16], but bone metastasis remains an incurable condition.…”

Section: Introductionmentioning

confidence: 78%

Osteosarcoma and Metastasis Associated Bone Degradation—A Tale of Osteoclast and Malignant Cell Cooperativity

Nørregaard

Jürgensen

Gårdsvoll

et al. 2021

IJMS

View full text Add to dashboard Cite

Cancer-induced bone degradation is part of the pathological process associated with both primary bone cancers, such as osteosarcoma, and bone metastases originating from, e.g., breast, prostate, and colon carcinomas. Typically, this includes a cancer-dependent hijacking of processes also occurring during physiological bone remodeling, including osteoclast-mediated disruption of the inorganic bone component and collagenolysis. Extensive research has revealed the significance of osteoclast-mediated bone resorption throughout the course of disease for both primary and secondary bone cancer. Nevertheless, cancer cells representing both primary bone cancer and bone metastasis have also been implicated directly in bone degradation. We will present and discuss observations on the contribution of osteoclasts and cancer cells in cancer-associated bone degradation and reciprocal modulatory actions between these cells. The focus of this review is osteosarcoma, but we will also include relevant observations from studies of bone metastasis. Additionally, we propose a model for cancer-associated bone degradation that involves a collaboration between osteoclasts and cancer cells and in which both cell types may directly participate in the degradation process.

show abstract

Epidemiology of bone metastases

Cited by 74 publications

References 40 publications

Molecular Mechanisms Leading from Periodontal Disease to Cancer

Molecular Mechanisms Leading from Periodontal Disease to Cancer

Mortality Trends from Urologic Cancers in Europe over the Period 1980–2017 and a Projection to 2025

Osteosarcoma and Metastasis Associated Bone Degradation—A Tale of Osteoclast and Malignant Cell Cooperativity

Contact Info

Product

Resources

About